These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 23846572)

  • 1. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto AG; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):345-53. PubMed ID: 24758569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing competitive and sustainable Polish generic medicines market.
    Simoens S
    Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Societal value of generic medicines beyond cost-saving through reduced prices.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):701-11. PubMed ID: 25695926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary generic market in Japan - key conditions to successful evolution.
    Jakovljevic MB; Nakazono S; Ogura S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):181-94. PubMed ID: 24450984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of French generic medicines retail market: why the use of generic medicines is limited.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):795-803. PubMed ID: 25095903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
    Zeng W
    BMC Health Serv Res; 2013 Oct; 13():390. PubMed ID: 24093493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does increased use of generic medicines by elders in Belgium help to contain escalating health care budgets?
    Dylst P; Vulto A; Simoens S
    J Aging Soc Policy; 2014; 26(3):266-80. PubMed ID: 24716815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.
    Kelton CM; Chang LV; Kreling DH
    Health Aff (Millwood); 2013 Jul; 32(7):1204-11. PubMed ID: 23836735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demand-side policies to encourage the use of generic medicines: an overview.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):59-72. PubMed ID: 23402447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
    Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
    PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. After years of steady growth, winds of restraint blowing on prescription-drug industry.
    Robinson A
    CMAJ; 1995 Jul; 153(1):85-8. PubMed ID: 7796380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Generic medicines].
    Peláez de Loño J
    Rev Enferm; 1999 Dec; 22(12):836-43. PubMed ID: 10797771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.